ReceptaBio. Extensive technological expertise to develop biosimilar drugs for oncologic application, through clinical tests with registration at Anvisa and FDA.


Biotechnology pro life

ReceptaBio is a Brazilian biotechnology company dedicated to the research and development of new drugs for the treatment of cancer. ReceptaBio was founded in 2006, result of a partnership of Brazilian businessmen with the Ludwig Cancer Research Institute (LCR), sharing the view that Brazil offers a significant set of competitive advantages for the development of biotechnology aimed at human health.

ReceptaBio develops biomolecules – monoclonal antibodies and peptides – with the ability to recognize and bind to specific targets in cells, acting directly on them or stimulating immune system actions on tumor cells, which makes their survival and reproduction unviable.

Monoclonal antibodies and peptides have been asserting themselves as an increasingly important therapeutic option in the treatment of several types of cancer, especially in the control and prevention of metastases. They may also be used as biomarkers for diagnosis and prognosis purposes of disease progression and/or response to treatments. Monoclonal antibodies are proteins, peptides are proteins fragments. The production of monoclonal antibodies is by a complex biotechnological process involving genetic engineering whereas peptides are produced by means of chemical synthesis.

ReceptaBio, when created, obtained the licensing of the intellectual property of four monoclonal antibodies that, in researches carried out by LCR, demonstrated potential for use in the treatment of various neoplasms. The collaboration with the LCR researchers guarantees to ReceptaBio an effective transfer of scientific and technological knowledge, providing greater quality and validation of its procedures.

ReceptaBio's Research & Development (R&D) activities are conducted according to an innovative model through collaborations with scientists from reference research institutions in the country, as well as renowned scientific consultants who assist in the identification and development of new antibodies and peptides.

ReceptaBio makes innovation in biotechnology to respond to the needs of society and the Brazilian market. All these actions are intended to translate into efficient drugs and cheaper treatments for the country's health system.

Progress has been made by ReceptaBio since its inception, highlighting the following facts:

Monoclonal Antibodies

01. Clinical tests

Mastery of all stages of the complex process of preparing and conducting clinical trials. Being the first Brazilian company to carry out Phase II clinical tests with monoclonal antibodies for cancer treatment with ANVISA and FDA registration.

Generation of lines

02. Humanized antibody

Mastery of the humanization and cell lines generation technology for the production of humanized monoclonal antibody.

Cancer treatment

03. Peptides

Discovery and patenting of peptides with potential for clinical use in the treatment of cancer, as verified in in vitro and in vivo pre-clinical tests.

Pharmaceutical sector

04. Alliances and partnerships

Proven ability to successfully establish and conduct alliances and partnerships with various private and public pharmaceutical sector agents.


05. Licensing

First licensing of a drug made by a Brazilian company to a foreign company.

ReceptaBio Staff

ReceptaBio Staff

Expertise, synergy and motivation to add value

Administration Board

  • Gabriel Luiz Oliva Perez (President)
  • Jonathan Skipper, PhD.
  • Jovelino de Carvalho Mineiro
  • Stephen Charles O’Sullivan
  • Bento Abreu Sodré de Carvalho Mineiro
  • Luciana Lages Tito
  • Thaigo Brandão da Cunha

Innovation Committee